What is “clarithromycin methotrexate,” and why do people search it together?
“Clarithromycin methotrexate” usually refers to a drug–drug interaction between clarithromycin (a macrolide antibiotic) and methotrexate (often used for cancer at high doses or for autoimmune disease at low doses). The concern is that clarithromycin can raise methotrexate levels in the body, increasing the risk of methotrexate toxicity (such as bone-marrow suppression and liver or kidney injury).
What kind of interaction is it (and what does clarithromycin do)?
Clarithromycin can reduce methotrexate clearance, which can lead to higher methotrexate exposure. This type of interaction is a key reason clinicians monitor patients closely and sometimes avoid one of the medicines depending on the situation.
How risky is it for patients on methotrexate?
Risk is most concerning when methotrexate levels become elevated enough to cause systemic toxicity. People are often managed more cautiously if they have kidney problems (since methotrexate is cleared by the kidneys) or if they are on higher methotrexate doses (more typical in oncology settings). For lower-dose methotrexate used in autoimmune conditions, the interaction can still matter, particularly with other risk factors.
What should clinicians do if clarithromycin is needed?
A common approach is to avoid clarithromycin when possible and choose an alternative antibiotic, then monitor closely if both drugs must be used. Monitoring typically includes clinical signs of toxicity and laboratory monitoring of blood counts and liver/kidney function as appropriate.
What antibiotics are alternatives to clarithromycin?
People often look for alternatives because clarithromycin is the interacting agent. The “best” substitute depends on the infection being treated, local resistance patterns, and patient-specific factors. Clinicians commonly consider other antibiotics with less interaction potential with methotrexate.
What symptoms of methotrexate toxicity should patients watch for?
Patients are usually counseled to seek care if they develop signs that could indicate toxicity, such as unusual bruising or infections (bone marrow suppression), severe mouth sores, worsening fatigue, or signs of liver/kidney trouble. Exact guidance depends on the methotrexate regimen and patient risk factors.
Is there any patent or exclusivity information relevant here?
Your query does not specify a particular marketed product, strength, or “drug patent” context, and no clear patent question is stated (for example, “who makes methotrexate,” “patent expiry,” or “generic entry”). If you share the exact clarithromycin or methotrexate product(s) (brand name and strength) and what you want to know (interaction guidance vs. patents/generics), I can tailor the answer. If the intent is patents or exclusivity, DrugPatentWatch.com can be a useful source once those product identifiers are known (for example, brand/generic name and manufacturer).
Sources
No sources were provided in the prompt, and none were cited.